Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Karen Sorensen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Apr 29
Vitrolife AB (Publ) Approves Dividend for the Financial Year 2024 Vitrolife AB (publ) at its AGM held on April 29, 2025, approved dividend of SEK 1.10 per share for the financial year 2024. 2 May, 2025 was adopted as the record day. Duyuru • Apr 10
Vitrolife AB (publ) Announces CFO Changes Vitrolife AB (publ) announced that Pär Ihrskog has been appointed CFO of the Vitrolife Group effective 10 October 2025. Pär currently serves as CFO at Bufab Group and brings a wealth of experience to the company, having also served as Group CFO/CIO at Embellence Group. He spent the majority of his career working in finance roles, of increasing seniority in SKF, also living and working in several countries, including the U.S. and China. Pär holds a master’s degree in business administration. Helena Wennerström will remain as acting CFO until Pär takes office. Duyuru • Mar 31
Vitrolife AB (Publ) Appoints Rickard Ericsson as Svp Innovation Vitrolife AB (publ) announced that Rickard Ericsson, formerly SVP Consumables and SVP Sales & Marketing, has been appointed SVP Innovation, effective immediately. With over ten years at the company, Rickard brings a deep understanding of the reproductive health market. In this new role, he will oversee R&D, Strategy & Sustainability, Portfolio Lifecycle Management, and Market Access. The Executive Management Team (EMT) now consists of: CEO: Bronwyn Brophy O'Connor Acting CFO: Helena Wennerström, COO: Ermanno Sironi, SVP Innovation: Rickard Ericsson, SVP Sales & Marketing: Olivia Natens, CHRO: Jessica Jonasson. Duyuru • Feb 21
The Vitrolife Group Appoints Ermanno Sironi as Chief Operating Officer The Vitrolife Group appointed Ermanno Sironi as Chief Operating Officer effective immediately. The COO will oversee the three business areas, Consumables, Technologies and Genetics as well as the IT organisation. The appointment supports continued execution of the corporate strategy to drive operational excellence, implementing a scalable operating model, optimising processes to realise synergies and leveraging digitalisation to increase productivity. Ermanno Sironi is a tenured MedTech executive with over 30 years' experience working in Operations, Finance and Business Development in global companies. Over the past year, he has served as a strategic advisor on operational excellence and business transformation to the Vitrolife Group's executive management team. Duyuru • Jan 31
Vitrolife AB (publ), Annual General Meeting, Apr 29, 2025 Vitrolife AB (publ), Annual General Meeting, Apr 29, 2025. Location: gothenburg, Sweden Duyuru • Jan 30
Vitrolife AB (Publ) Proposes Dividend The Board of Vitrolife AB (publ) proposed to the Annual General Meeting a dividend of SEK 149 (135) million, corresponding to SEK 1.10 (1.00) per share. Duyuru • Dec 03
Vitrolife AB (Publ) Announces Chief Financial Officer Changes Vitrolife AB (publ) announced that Patrik Tolf will be stepping down as Chief Financial Officer due to personal reasons. Helena Wennerström will assume the role of acting CFO. Helena has extensive experience in finance and business management, including having served as CFO at ViaCon Group AB and EVP & CFO at Bulten AB. Helena Wennerström will immediately assume the role of acting CFO and Patrik will be here to support her during a transition period. The recruitment of a permanent CFO is being initiated. Duyuru • Nov 16
Vitrolife AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025 Vitrolife AB (publ) announced that they will report fiscal year 2024 final results on Mar 27, 2025 Duyuru • Oct 27
Vitrolife AB (publ) to Report Q4, 2025 Results on Jan 29, 2026 Vitrolife AB (publ) announced that they will report Q4, 2025 results on Jan 29, 2026 Reported Earnings • Oct 24
Third quarter 2024 earnings released: EPS: kr0.86 (vs kr0.90 in 3Q 2023) Third quarter 2024 results: EPS: kr0.86 (down from kr0.90 in 3Q 2023). Revenue: kr867.0m (up 2.2% from 3Q 2023). Net income: kr116.0m (down 4.9% from 3Q 2023). Profit margin: 13% (in line with 3Q 2023). Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance. Duyuru • Oct 04
Vitrolife AB (Publ) Announces Election Committee Appointments Vitrolife AB (publ) announced the following people have been appointed as members of the election committee for Vitrolife AB for the Annual General Meeting in 2025: Niels Jacobsen, appointed by William Demant Invest A/S; Patrik Tigerschiöld, appointed by Bure Equity AB; Patricia Hedelius, appointed by AMF Fonder & Pension; Jón Sigurdsson, Chairman of the Board. The appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at the Annual General Meeting of Vitrolife AB on April 25, 2024. Buy Or Sell Opportunity • Sep 27
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 41% to €21.32. The fair value is estimated to be €17.59, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 28% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Sep 02
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 42% to €21.94. The fair value is estimated to be €18.07, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 28% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Jul 18
Second quarter 2024 earnings released: EPS: kr1.06 (vs kr0.78 in 2Q 2023) Second quarter 2024 results: EPS: kr1.06 (up from kr0.78 in 2Q 2023). Revenue: kr941.0m (up 4.0% from 2Q 2023). Net income: kr143.0m (up 35% from 2Q 2023). Profit margin: 15% (up from 12% in 2Q 2023). Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 94 percentage points per year, which is a significant difference in performance. Buy Or Sell Opportunity • Jul 05
Now 19% undervalued after recent price drop Over the last 90 days, the stock has fallen 5.2% to €14.91. The fair value is estimated to be €18.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Jul 04
Now 19% undervalued after recent price drop Over the last 90 days, the stock has fallen 5.7% to €14.83. The fair value is estimated to be €18.27, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Jul 03
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 8.0% to €14.91. The fair value is estimated to be €18.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Meanwhile, the company became loss making. Duyuru • May 23
Vitrolife AB (publ) (OM:VITR) acquired Stb Zorg B.V. Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million on May 2, 2024. The initial purchase price, on a net debt free basis is €9.6 million which will be paid at closing. In addition, there is an earn-out component, structured over a 3-year period, based on scale up and achievement of sales growth milestones to a maximum payout of €8.4 million. eFertility will be reported under the Technologies business area. The expected closing is mid-May 2024 and will be financed through the Vitrolife Group´s cash.Vitrolife AB (publ) (OM:VITR) completed the acquisition of Stb Zorg B.V. on May 22, 2024. In 2023, Stb Zorg B.V. had revenues of €1.5 million. Duyuru • May 03
Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million. Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million on May 2, 2024. The initial purchase price, on a net debt free basis is €9.6 million which will be paid at closing. In addition, there is an earn-out component, structured over a 3-year period, based on scale up and achievement of sales growth milestones to a maximum payout of €8.4 million. eFertility will be reported under the Technologies business area. The expected closing is mid-May 2024 and will be financed through the Vitrolife Group´s cash. Duyuru • Apr 27
Vitrolife AB (Publ) Approves Dividend for the Financial Year 2023 Vitrolife AB (publ) at the Annual General Meeting held on 25 April 2024, approved dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the record day. Upcoming Dividend • Apr 21
Upcoming dividend of kr1.00 per share Eligible shareholders must have bought the stock before 26 April 2024. Payment date: 03 May 2024. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.6%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (1.8%). Buy Or Sell Opportunity • Apr 19
Now 24% undervalued The stock has been flat over the last 90 days, currently trading at €14.18. The fair value is estimated to be €18.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Apr 18
First quarter 2024 earnings released: EPS: kr0.85 (vs kr0.74 in 1Q 2023) First quarter 2024 results: EPS: kr0.85 (up from kr0.74 in 1Q 2023). Revenue: kr841.0m (down 1.5% from 1Q 2023). Net income: kr115.0m (up 15% from 1Q 2023). Profit margin: 14% (up from 12% in 1Q 2023). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 92 percentage points per year, which is a significant difference in performance. Declared Dividend • Apr 07
Dividend of kr1.00 announced Shareholders will receive a dividend of kr1.00. Ex-date: 26th April 2024 Payment date: 3rd May 2024 Dividend yield will be 6.4%, which is higher than the industry average of 2.8%. Reported Earnings • Feb 03
Full year 2023 earnings released: kr28.44 loss per share (vs kr2.91 profit in FY 2022) Full year 2023 results: kr28.44 loss per share (down from kr2.91 profit in FY 2022). Revenue: kr3.51b (up 8.6% from FY 2022). Net loss: kr3.85b (down kr4.25b from profit in FY 2022). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance. Duyuru • Jan 24
Vitrolife AB (Publ) Reports Non-Cash Impairment for the Fourth Quarter of 2023 Vitrolife AB (publ) reported non-cash impairment for the fourth quarter of 2023. Non-cash impairment of SEK 4.3 billion in the fourth quarter 2023, relating to the impairment of goodwill attributed to the acquisition of Igenomix in 2021. Buying Opportunity • Nov 14
Now 20% undervalued Over the last 90 days, the stock is up 5.6%. The fair value is estimated to be €16.69, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 40% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 19% in 2 years. Earnings is forecast to grow by 87% in the next 2 years. Reported Earnings • Oct 28
Third quarter 2023 earnings released: EPS: kr0.90 (vs kr0.80 in 3Q 2022) Third quarter 2023 results: EPS: kr0.90 (up from kr0.80 in 3Q 2022). Revenue: kr848.0m (up 6.3% from 3Q 2022). Net income: kr122.0m (up 13% from 3Q 2022). Profit margin: 14% (in line with 3Q 2022). Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings. Duyuru • Oct 06
Vitrolife AB (publ) Announces Election Committee Appointments Vitrolife AB (publ) announced the following people have been appointed as members of the election committee for the Annual General Meeting in 2024: Niels Jacobsen, appointed by William Demant Invest A/S; Patrik Tigerschiöld, appointed by Bure Equity AB; Caroline Sjösten, appointed by Swedbank Robur Fonder AB; and Jón Sigurdsson, Chairman of the Board. Duyuru • Aug 24
Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice President Vitrolife AB (publ) announced that Maria Forss, has resigned from her position as SVP Consumables business area in the company as she will assume the role of CEO BICO Group AB. Maria has been employed within the company since 2012 and has been leading the Consumables business area since 2017. Board Change • Aug 03
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Karen Sorensen was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Aug 01
Vitrolife AB Announces Board Changes Vitrolife AB (publ) announced, Henrik Blomquist will step down as Chairman of the Board of Vitrolife AB (publ) and the Board of Directors has appointed Jón Sigurdsson as the Chairman of the Board with effect from August 1, 2023, when Bronwyn Brophy assumes the position as CEO. The board member Vesa Koskinen, appointed by EQT VIII has at his own request chosen to resign from the Board of Directors of Vitrolife AB (publ). Vesa Koskinen has been a board member since 1 December 2021 and will step down as of today. After the announced changes, the Board consists of the Chairman of the Board Jón Sigurdsson and the board members Henrik Blomquist, Karen Lykke Sørensen, Lars Holmqvist and Pia Marions. Henrik Blomquist will replace Vesa Koskinen in the Audit Committee. Valuation Update With 7 Day Price Move • Jul 21
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to €13.87, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 36x in the Biotechs industry in Europe. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €14.15 per share. New Risk • Jul 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Jul 14
Second quarter 2023 earnings released: EPS: kr0.78 (vs kr0.96 in 2Q 2022) Second quarter 2023 results: EPS: kr0.78 (down from kr0.96 in 2Q 2022). Revenue: kr905.0m (up 9.2% from 2Q 2022). Net income: kr106.0m (down 19% from 2Q 2022). Profit margin: 12% (down from 16% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jun 17
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €20.88, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 28x in the Biotechs industry in Europe. Total returns to shareholders of 4.2% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €14.55 per share. Recent Insider Transactions • May 04
Chief Financial Officer recently bought €47k worth of stock On the 26th of April, Patrik Tolf bought around 3k shares on-market at roughly €18.78 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Patrik has been a buyer over the last 12 months, purchasing a net total of €96k worth in shares. Upcoming Dividend • Apr 21
Upcoming dividend of kr0.85 per share at 0.4% yield Eligible shareholders must have bought the stock before 28 April 2023. Payment date: 05 May 2023. Payout ratio is a comfortable 29% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (2.5%). Reported Earnings • Apr 02
Full year 2022 earnings released: EPS: kr2.91 (vs kr2.98 in FY 2021) Full year 2022 results: EPS: kr2.91. Revenue: kr3.23b (up 92% from FY 2021). Net income: kr394.0m (up 16% from FY 2021). Profit margin: 12% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Post-clinical trial products Launched (during full year): 2 Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Germany. Reported Earnings • Feb 04
Full year 2022 earnings released: EPS: kr2.91 (vs kr2.98 in FY 2021) Full year 2022 results: EPS: kr2.91. Revenue: kr3.23b (up 92% from FY 2021). Net income: kr394.0m (up 16% from FY 2021). Profit margin: 12% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe. Duyuru • Feb 01
Vitrolife AB (publ) Announces Executive Changes Vitrolife AB (publ) appointed Bronwyn Brophy as new CEO. Bronwyn Brophy has an impressive track record as a leader of global Life science and Medtech businesses. The Board of directors of the company find Bronwyn Brophy to be an exceptional candidate to effectuate Vitrolife's strategy to reach the company's full potential and thereby create increased shareholder value. Bronwyn Brophy is Irish and has extensive experience of leading positions in Global Life Science and Medtech companies such as Thermo Fisher Scientific, Medtronic and Johnson & Johnson. The last years within Thermo Fischer Bronwyn Brophy was heading the Immunodiagnostics Division globally and before that served as President of the EMEA region. Bronwyn Brophy will join the company at the latest on 1 August 2023. As notified 12 September 2022, Thomas Axelsson will leave his position as CEO. This is expected to occur 31 March 2023. At that time Jón Sigurdsson, Chairman of the board, will assume the position as interim CEO until Bronwyn Brophy starts her appointment. Consequently, the board of directors has appointed the current board member Henrik Blomquist as chairman of the board until the annual general meeting 27 April 2023. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: kr0.80 (vs kr0.89 in 3Q 2021) Third quarter 2022 results: EPS: kr0.80. Revenue: kr798.0m (up 97% from 3Q 2021). Net income: kr108.0m (up 3.5% from 3Q 2021). Profit margin: 14% (down from 26% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany. Duyuru • Oct 11
Vitrolife AB (publ) Announces Election Committee Appointments Vitrolife AB (publ) announced that the following people have been appointed as members of Vitrolife's election committee for the Annual General Meeting in 2023: Niels Jacobsen, appointed by William Demant Invest A/S; Patrik Tigerschiöld, appointed by Bure Equity AB; Erika Henriksson, appointed by EQT VIII; and Jón Sigurdsson, Chairman of the Board. Valuation Update With 7 Day Price Move • Sep 24
Investor sentiment deteriorated over the past week After last week's 18% share price decline to €17.23, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 26x in the Biotechs industry in Europe. Total returns to shareholders of 16% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €20.53 per share. Buying Opportunity • Sep 23
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 5.7%. The fair value is estimated to be €23.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has declined by 4.2%. Revenue is forecast to grow by 59% in 2 years. Earnings is forecast to grow by 105% in the next 2 years. Duyuru • Sep 13
Vitrolife AB (Publ) Announces Retirement of Thomas Axelsson as CEO Vitrolife AB (publ) announced that Thomas Axelsson, CEO of the company informed the Board of Directors of his desire and intention to retire and be released from his position. Consequently, the process to find a new CEO to replace Thomas will immediately begin and will be led by Jon Sigurdsson, Chairman of the Board. Thomas will remain as the CEO until the recruitment process is finalized. Reported Earnings • Jul 17
Second quarter 2022 earnings released: EPS: kr0.96 (vs kr0.79 in 2Q 2021) Second quarter 2022 results: EPS: kr0.96 (up from kr0.79 in 2Q 2021). Revenue: kr829.0m (up 117% from 2Q 2021). Net income: kr130.0m (up 51% from 2Q 2021). Profit margin: 16% (down from 23% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 37%, compared to a 31% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Duyuru • Jul 08
Vitrolife AB (publ), Annual General Meeting, Apr 27, 2023 Vitrolife AB (publ), Annual General Meeting, Apr 27, 2023. Recent Insider Transactions • May 04
Chief Financial Officer recently bought €48k worth of stock On the 29th of April, Patrik Tolf bought around 2k shares on-market at roughly €23.97 per share. This was the largest purchase by an insider in the last 3 months. This was Patrik's only on-market trade for the last 12 months. Reported Earnings • Apr 27
First quarter 2022 earnings released: EPS: kr0.61 (vs kr1.09 in 1Q 2021) First quarter 2022 results: EPS: kr0.61 (down from kr1.09 in 1Q 2021). Revenue: kr752.0m (up 98% from 1Q 2021). Net income: kr82.0m (down 31% from 1Q 2021). Profit margin: 11% (down from 31% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 56%, compared to a 43% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Reported Earnings • Apr 23
First quarter 2022 earnings released: EPS: kr0.61 (vs kr1.09 in 1Q 2021) First quarter 2022 results: EPS: kr0.61 (down from kr1.09 in 1Q 2021). Revenue: kr752.0m (up 98% from 1Q 2021). Net income: kr82.0m (down 31% from 1Q 2021). Profit margin: 11% (down from 31% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 58%, compared to a 46% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Upcoming Dividend • Apr 21
Upcoming dividend of kr0.80 per share Eligible shareholders must have bought the stock before 28 April 2022. Payment date: 04 May 2022. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.9%). Lower than average of industry peers (1.4%). Duyuru • Mar 29
Vitrolife AB (Publ) Proposes Dividend The Board of Directors of Vitrolife AB (publ) proposed a dividend of SEK 0.80 per share and 29 April 2022 as the record day for the dividend, to its Annual General Meeting to be held on April 27, 2022. Reported Earnings • Feb 17
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: kr2.97 (up from kr2.64 in FY 2020). Revenue: kr1.68b (up 35% from FY 2020). Net income: kr341.0m (up 19% from FY 2020). Profit margin: 20% (down from 23% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.7%. Over the next year, revenue is forecast to grow 94%, compared to a 59% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Feb 16
Vitrolife AB (Publ) Proposes Dividend Vitrolife AB (publ) proposed a dividend of SEK 108 million, corresponding to SEK 0.80 per share, compared to SEK 0.80 per share a year ago. Reported Earnings • Oct 30
Third quarter 2021 earnings released: EPS kr0.89 (vs kr0.81 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: kr405.6m (up 27% from 3Q 2020). Net income: kr104.3m (up 18% from 3Q 2020). Profit margin: 26% (down from 28% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 57% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Jul 17
Second quarter 2021 earnings released: EPS kr0.79 (vs kr0.11 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr382.0m (up 83% from 2Q 2020). Net income: kr85.8m (up kr74.2m from 2Q 2020). Profit margin: 23% (up from 5.6% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Apr 29
Vitrolife AB (publ) Approves Dividend for the Financial Year 2020 At the Vitrolife AB (publ)’s Annual General Meeting held on April 28, 2021, the company approved dividend of SEK 0.80 per share for the financial year 2020. April 30, 2021 was adopted as the record day. Reported Earnings • Apr 24
First quarter 2021 earnings released: EPS kr1.09 (vs kr0.73 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr379.0m (up 14% from 1Q 2020). Net income: kr118.2m (up 48% from 1Q 2020). Profit margin: 31% (up from 24% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Apr 22
Upcoming dividend of kr0.80 per share Eligible shareholders must have bought the stock before 29 April 2021. Payment date: 05 May 2021. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (0.5%). Reported Earnings • Apr 01
Full year 2020 earnings released: EPS kr2.64 (vs kr3.53 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: kr1.25b (down 16% from FY 2019). Net income: kr286.8m (down 25% from FY 2019). Profit margin: 23% (down from 26% in FY 2019). The decrease in margin was driven by lower revenue. Post-clinical trial products Launched (during full year): 2 Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Feb 12
Full year 2020 earnings released: EPS kr2.64 (vs kr3.53 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: kr1.25b (down 16% from FY 2019). Net income: kr286.8m (down 25% from FY 2019). Profit margin: 23% (down from 26% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth. Analyst Estimate Surprise Post Earnings • Feb 12
Revenue misses expectations Revenue missed analyst estimates by 0.2%. Over the next year, revenue is forecast to grow 18%, compared to a 80% growth forecast for the Biotechs industry in Germany. Is New 90 Day High Low • Feb 03
New 90-day high: €22.60 The company is up 2.0% from its price of €22.20 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.49 per share. Duyuru • Jan 22
Vitrolife AB (publ) to Report Fiscal Year 2020 Results on Feb 10, 2021 Vitrolife AB (publ) announced that they will report fiscal year 2020 results at 8:00 AM, Central European Standard Time on Feb 10, 2021 Is New 90 Day High Low • Nov 16
New 90-day low: €20.14 The company is down 10.0% from its price of €22.46 on 18 August 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.55 per share. Reported Earnings • Nov 07
Third quarter 2020 earnings released: EPS kr0.81 The company reported a poor third quarter result with weaker earnings and revenues, although profit margins were flat. Third quarter 2020 results: Revenue: kr320.1m (down 15% from 3Q 2019). Net income: kr88.2m (down 17% from 3Q 2019). Profit margin: 28% (in line with 3Q 2019). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth. Analyst Estimate Surprise Post Earnings • Nov 07
Revenue beats expectations Revenue exceeded analyst estimates by 4.7%. Over the next year, revenue is forecast to grow 12%, compared to a 321% growth forecast for the Biotechs industry in Germany. Duyuru • Nov 07
Vitrolife AB (publ) to Report Fiscal Year 2020 Results on Mar 30, 2021 Vitrolife AB (publ) announced that they will report fiscal year 2020 results at 6:46 AM, GMT Standard Time on Mar 30, 2021 Duyuru • Nov 06
Vitrolife AB (publ) to Report Q1, 2021 Results on Apr 22, 2021 Vitrolife AB (publ) announced that they will report Q1, 2021 results at 6:46 AM, GMT Standard Time on Apr 22, 2021 
